Cargando…
Karonudib has potent anti-tumor effects in preclinical models of B-cell lymphoma
Chemo-immunotherapy has improved survival in B-cell lymphoma patients, but refractory/relapsed diseases still represent a major challenge, urging for development of new therapeutics. Karonudib (TH1579) was developed to inhibit MTH1, an enzyme preventing oxidized dNTP-incorporation in DNA. MTH1 is hi...
Autores principales: | Oksvold, Morten P., Berglund, Ulrika Warpman, Gad, Helge, Bai, Baoyan, Stokke, Trond, Rein, Idun Dale, Pham, Therese, Sanjiv, Kumar, Øy, Geir Frode, Norum, Jens Henrik, Smeland, Erlend B., Myklebust, June H., Helleday, Thomas, Våtsveen, Thea Kristin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7973795/ https://www.ncbi.nlm.nih.gov/pubmed/33737576 http://dx.doi.org/10.1038/s41598-021-85613-8 |
Ejemplares similares
-
Karonudib is a promising anticancer therapy in hepatocellular carcinoma
por: Hua, Xiangwei, et al.
Publicado: (2019) -
A patient-derived xenograft pre-clinical trial reveals treatment responses and a resistance mechanism to karonudib in metastatic melanoma
por: Einarsdottir, Berglind O., et al.
Publicado: (2018) -
Correction: A patient-derived xenograft pre-clinical trial reveals treatment responses and a resistance mechanism to karonudib in metastatic melanoma
por: Einarsdottir, Berglind O., et al.
Publicado: (2020) -
MutT Homolog 1 Inhibitor Karonudib Attenuates Autoimmune Hepatitis by Inhibiting DNA Repair in Activated T Cells
por: Chen, Yong, et al.
Publicado: (2021) -
New distinct compartments in the G(2) phase of the cell cycle defined by the levels of γH2AX.
por: Dale Rein, Idun, et al.
Publicado: (2015)